PGK1 and amyotrophic lateral sclerosis: Here, we demonstrate that directly targeting PGK1 activity, including via treatment with terazosin, has the potential to act as a neuroprotective agent in ALS, ameliorating disease phenotypes both in vivo and in vitro across species and gene mutations.